Barkan Pharma Israel Ltd. takes a novel approach to the development of pharmacological

compounds that will bolster the body’s systems, providing safe, effective and affordable protection

against radiation.

ATRP-704 presents a preventive treatment for cancer radiotherapy or any other threats of an

environmental ionizing radiation. In the race to meet today's demand for ionization radiation

treatment, historical development failures are brushed aside despite the increasing dangers.

Such hazards exist for the thousands of civilians living and working in large metropolitan areas. All

are subjected to radiation from medicine or industry, and there is even a risk for potential mass

casualty radiation. Much effort has recently been invested in developing an innovative

radioprotection drug. Hence, the new drug developed by Barkan Pharma Israel Ltd (ATRP-704) has

a vast potential for these vital needs.

The overall mechanisms of Isothioroniums are aimed to suppress the apoptotic signals.

The mechanisms of radioprotection of thiol compounds are several and complex, including:*:

(1) H-atom donation.

(2) Creation of hypoxia around the decay site.

(3) Inhibition of NO synthesis.

(4) Inducing free radical scavenging enzymes.

* V.R. Narra et. al. The j. of Nuclear Med. Val. 36, No. 2. Feb. 1995

The Company’s leading candidate: ATRP-704 now entered a late-stage development for the

treatment of Acute Radiation Syndrome (ARS), a life-threatening condition resulting from exposure

to high levels of radiation.

ATRP-704

For Radiation Protection